Varex Bio is a biotechnology company founded by former GW Pharmaceuticals executives, focused on advancing next-generation cannabinoid therapeutics. The company is developing tetrahydrocannabivarin (THCV) as a novel treatment for central nervous system disorders, leveraging deep expertise in cannabinoid pharmacology, drug development, and regulatory strategy. By combining proven translational approaches with a differentiated cannabinoid profile, Varex aims to unlock new therapeutic pathways for patients with unmet needs across neurology and psychiatry.
